ASCIONE, LILIANA
ASCIONE, LILIANA
Universita' degli Studi di MILANO
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit
2024 A. Esposito, E. Crimini, C. Criscitiello, C. Belli, R. Scafetta, R. Scalia, G. Castellano, E. Giordano, J. Katrini, L. Ascione, L. Boscolo Bielo, M. Repetto, A. Marra, D. Trapani, G.M. Varano, D. Maiettini, P. Della Vigna, F. Orsi, E. Guerini Rocco, N. Fusco, G. Curigliano
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience
2024 E. Crimini, G. Tini, P. Tarantino, L. Ascione, M. Repetto, P. Beria, A. Ranghiero, A. Marra, C. Belli, C. Criscitiello, A. Esposito, E. Guerini Rocco, M.C.P. Barberis, L. Mazzarella, G. Curigliano
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases
2023 P. Trillo, J. Sandoval, D. Trapani, E. Nicolò, P. Zagami, F. Giugliano, P. Tarantino, G. Vivanet, L. Ascione, A. Friedlaender, A. Esposito, C. Criscitiello, G. Curigliano
Screening Programs for Breast Cancer: Toward Individualized, Risk-Adapted Strategies of Early Detection
2023 D. Trapani, J. Sandoval, P.T. Aliaga, L. Ascione, P.P. Maria Berton Giachetti, G. Curigliano, O. Ginsburg
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience
2023 M. Repetto, E. Crimini, L. Boscolo Bielo, E. Guerini-Rocco, L. Ascione, A. Bonfanti, C. Zanzottera, L. Mazzarella, A. Ranghiero, C. Belli, C. Criscitiello, A. Esposito, M.C.P. Barberis, G. Curigliano
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
2023 L. Ascione, E. Crimini, D. Trapani, A. Marra, C. Criscitiello, G. Curigliano
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study
2023 S. Morganti, A. Marra, S. Gandini, L. Ascione, M. Ivanova, K. Venetis, E. Sajjadi, P. Zagami, F. Giugliano, B. Taurelli Salimbeni, P.P.M. Berton Giachetti, C. Corti, E. De Camilli, G. Curigliano, N. Fusco, C. Criscitiello
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer
2022 S. Morganti, A. Marra, K. Venetis, E. Sajjadi, L. Ascione, C. Corti, P. Zagami, M. Ivanova, L. Zattoni, G. Curigliano, N. Fusco, C. Criscitiello
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population
2022 L. Mazzarella, F. Giugliano, E. Nicolo', E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, I. Minchella, C. Belli, A. Esposito, M. Locatelli, C. Criscitiello, G. Curigliano
PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
2022 L. Ascione, P. Zagami, E. Nicolò, E. Crimini, G. Curigliano, C. Criscitiello
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
2022 E. Nicolò, F. Giugliano, L. Ascione, P. Tarantino, C. Corti, S.M. Tolaney, M. Cristofanilli, G. Curigliano
Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
2022 S. Morganti, M. Ivanova, E. Ferraro, L. Ascione, G. Vivanet, G. Bonizzi, G. Curigliano, N. Fusco, C. Criscitiello